highly significantp < 0.0001
standard 5 mg versus reduced 2.5 mg twice daily) and differing proportions of dialysis-dependent versus non-dialysis advanced CKD patients across the included studies." Meta-regression confirmed that the specific DOAC agent was a highly significant moderator of bleeding risk (Q M = 22.88, p < 0.0001).